Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON Sun Aug 24, 2014 12:25pm EDT

LONDON Aug 24 (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector, Roche said on Sunday.

The Swiss drugmaker will pay $74.00 a share for InterMune, representing a premium of 38 percent to the closing price on Aug. 22. (Reporting by Ben Hirschler, Editing by Angus MacSwan)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article